Journal Article10.1038/NRD3229
Development trends for human monoclonal antibody therapeutics
1K
TL;DR: Data is analysed on 147 human mAbs that have entered clinical study to highlight trends in their development and approval, which may help inform future studies of this class of therapeutic agents.
read more
Abstract: Fully human monoclonal antibodies (mAbs), which have the potential to be less immunogenic than earlier humanized and chimeric mAbs, are the most rapidly growing class of mAbs in clinical development. Here, Reichert and colleagues highlight trends in the development of human mAbs, seven of which have so far gained regulatory approval.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Antibody therapy of cancer
TL;DR: This Review outlines the fundamental strategies that are required to develop antibody therapies for cancer patients through iterative approaches to target and antibody selection, extending from preclinical studies to human trials.
2K
Contribution of Organofluorine Compounds to Pharmaceuticals.
Munenori Inoue,Yuji Sumii,Norio Shibata,Norio Shibata +3 more
- 22 Apr 2020
TL;DR: This mini-review analyzes the prevalence of fluoro-pharmaceuticals in the market and categorizes them into several groups based on the chemotype of thefluoro-functional groups, their therapeutic purpose, and the presence of heterocycles and/or chirality to highlight the structural motifs, patterns, and promising trends in fluorine-based drug design.
1.2K
Nanomedicine(s) under the Microscope
Ruth Duncan,Rogério Gaspar +1 more
TL;DR: Both nanomedicines in clinical use and emerging nanosized drugs, drug delivery systems, imaging agents, and theranostics with unique properties that promise much for the future are reviewed.
965
The evolution of commercial drug delivery technologies.
TL;DR: In this article, the authors discuss seminal approaches that led to the development of successful therapeutic products involving small molecules and macromolecules, identify three drug delivery paradigms that form the basis of contemporary drug delivery and discuss how they have aided the initial clinical successes of each class of therapeutic.
Plant adaptation to drought stress.
TL;DR: The crop plant model rice ( Oryza sativa) is used here as an example to highlight mechanisms and genes for adaptation of crop plants to drought stress.
775
References
•Journal Article
Treatment of Septic Shock with Human Monoclonal Antibody HA-1A
TL;DR: In this paper, the authors compared the effectiveness of 100 mg of HA-1A and placebo in reducing the 14-day all-cause mortality rate in patients with septic shock and gram-negative bacteremia in the Centocor.
113
Mining human antibody repertoires.
Roger R. Beerli,Christoph Rader +1 more
TL;DR: The selection of human mAbs from naïve, immune, transgenic, and synthetic human antibody repertoires using methods based on hybridoma technology, clonal expansion of peripheral B cells, single-cell PCR, phage display, yeast display, and mammalian cell display are discussed.
62
Antiendotoxin antibodies: a dead end?
TL;DR: The findings in a follow-up study of the HA-1A monoclonal antibody in a patient subpopulation that, in the first study, appeared to derive benefit from HA- 1A: those with shock and documented gram-negative bacteremia satisfied the safety stopping rule for the study.
55
HAHA--nothing to laugh about. Measuring the immunogenicity (human anti-human antibody response) induced by humanized monoclonal antibodies applying ELISA and SPR technology.
TL;DR: Within this article, enzyme-linked immunosorbent assay (ELISA) and surface plasmon resonance (SPR) methodology to measure immunogenicity are compared and the pros and cons are discussed.
51